Skip to main content

Table 7 Risk features of myelofibrosis in MDS patients underwent HSCT by Cox regression analysis (n = 141)

From: Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome

Variable Relapse NRM DFS OS
Univariate Multivariate Univariate Multivariate Univariate Multivariate Univariate Multivariate
  P   P   P   P
  HR (95% CI)   HR (95% CI)   HR (95% CI)   HR (95% CI)
Age 0.988 – 0.169 – 0.21 – 0.21 –
  1.00 (0.96–1.04)   1.02 (0.99–1.05)   1.02 (0.99–1.04)   1.02 (0.99–1.04)  
Sex   –   –   –   –
 Male Ref.   Ref.   Ref.   Ref.  
 Female 0.566   0.304   0.245   0.319  
  0.76 (0.30–1.93)   0.70 (0.36–1.38)   0.72 (0.42–1.25)   0.74 (0.41–1.34)  
Cytogenetics         
 Non–complex karyotypes Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
 Complex karyotypes 0.012 0.006 0.328 0.347 0.012 0.020 0.014 0.009
  3.51 (1.32–9.34) 4.16 (1.51–11.45) 1.51 (0.66–3.46) 1.51 (0.64–3.55) 2.24 (1.19–4.20) 2.16 (1.13–4.12) 2.28 (1.18–4.42) 2.47 (1.25–4.90)
BM blasts at HSCT         
  ≤ 5% Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
  > 5% 0.349 0.253 0.343 0.245 0.782 0.773 0.763 0.73
  1.80 (0.53–6.20) 2.08 (0.59–7.31) 0.72 (0.36–1.43) 0.66 (0.33–1.33) 0.92 (0.51–1.66) 0.92 (0.51–1.66) 0.91 (0.48–1.72) 0.89 (0.47–1.69)
Myelofibrosis         
 MF = 0/1 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
 MF = 2/3 0.964 0.914 0.986 0.286 0.459 0.396 0.569 0.444
  0.97 (0.28–3.34) 1.07 (0.31–3.76) 1.02 (0.13–8.15) 0.56 (0.20–1.62) 0.74 (0.34–1.64) 0.71 (0.32–1.58) 0.78 (0.33–1.84) 0.71 (0.30–1.70)
Time to HSCT from diagnosis
  ≤ 6 months Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
  > 6 months 0.77 0.888 0.56 0.709 0.952 0.678 0.741 0.526
  0.86 (0.31–2.39) 1.08 (0.38–3.08) 0.63 (0.13–3.02) 1.15 (0.56–2.34) 1.02 (0.58–1.80) 1.13 (0.63–2.04) 1.11 (0.60–2.04) 1.23 (0.65–2.31)
Previous therapy for MDS
 No cytoreductive treatments Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
 Cytoreductive treatments 0.468 0.327 0.337 0.642 0.902 0.856 0.794 0.627
  1.41 (0.56–3.60) 1.61 (0.62–4.19) 1.97 (0.49–7.89) 0.86 (0.45–1.64) 0.97 (0.57–1.63) 1.05 (0.62–1.79) 1.08 (0.61–1.91) 1.16 (0.64–2.07)
Donor source
 HID Ref – Ref – Ref – Ref –
 MUD 0.806   0.277   0.709   0.903  
  0.77 (0.09–6.50)   2.49 (0.48–12.81)   0.82 (0.28–2.37)   1.07 (0.37–3.13)  
 MSD 0.393   0.374   0.646   0.717  
  1.54 (0.57–4.11)   0.48 (0.09–2.45)   0.88 (0.51–1.51)   0.90 (0.50–1.62)  
Stem cell source
 PB Ref – Ref – Ref – Ref –
 PB + BM 0.325   0.628   0.899   0.666  
  1.60 (0.63–4.07)   0.85 (0.45–1.62)   1.03 (0.61–1.74)   1.13 (0.64–2.00)  
  1. NRM non-replase mortality, RI relapse incidence, DFS disease-free survival, OS overall survival (after allo-HSCT), MF myelofibrosis
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us